My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

35.04 +0.14 (+0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
From Royalty Pharma plc
Via GlobeNewswire
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
How Do Investors Really Feel About Royalty Pharma?
 
Via Benzinga
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
From Royalty Pharma plc
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
From Royalty Pharma plc
Via GlobeNewswire
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Topics Economy
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
From Royalty Pharma plc
Via GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
From Zenas BioPharma
Via GlobeNewswire
1 of Wall Street’s Favorite Stock to Keep an Eye On and 2 We Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
From Royalty Pharma plc
Via GlobeNewswire
1 Value Stock with Exciting Potential and 2 We Avoid
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings
Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks. 
Via Chartmill
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today
 
Via Benzinga
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14... 
Via StockStory
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Royalty Pharma (RPRX) Q2 Receipts Up 20%
Via The Motley Fool
Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance
Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence. 
Via Chartmill
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per... 
Via StockStory
Royalty Pharma Reports Second Quarter 2025 Results
From Royalty Pharma plc
Via GlobeNewswire
Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Government World Trade
2 Reasons to Watch RPRX and 1 to Stay Cautious
Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its... 
Via StockStory
Topics Stocks
3 Profitable Stocks to Research Further
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting... 
Via StockStory
Topics Supply Chain
Royalty Pharma Declares Third Quarter 2025 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.